 Psychedelic-focused biotech company Mind Medicine Inc. NASDAQ: MNMD NEO: MMED DE: MMQ recently met with the US Food and Drug Administration FDA Center for Devices and Radiological Health CDRH with consultation from the Center for Drug Evaluation and Research CDER to discuss several key points for ongoing development of the MindMed Session Monitoring System. During a device pre-submission meeting, which was held on October 25, MindMed presented the FDA with a working Indications for Use statement IFU and a development roadmap. 